US FDA approves expanded indication for BRILINTA to include long-term use in patients with a history of heart attack
- Details
- Category: AstraZeneca
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved BRILINTA® (ticagrelor) tablets at a new 60mg dose to be used in patients with a history of heart attack beyond the first year. With this expanded indication, BRILINTA is now approved to reduce the rate of cardiovascular death, myocardial infarction (MI, also known as heart attack) and stroke in patients with acute coronary syndrome (ACS) or a history of MI.
Sanofi to collaborate with Google life sciences to improve diabetes health outcomes
- Details
- Category: Sanofi
Sanofi and the life sciences team at Google are collaborating to improve care and outcomes for people with type 1 and type 2 diabetes. The collaboration will pair Sanofi's leadership in diabetes treatments and devices with Google's expertise in analytics, miniaturized electronics and low power chip design.
Novartis announces global partnership with Amgen to develop and commercialize pioneering neuroscience treatments
- Details
- Category: Novartis
Novartis has entered into a global collaboration with Amgen to commercialize and develop pioneering neuroscience treatments. The companies will partner in the development and commercialization of a BACE inhibitor program in Alzheimer's Disease (AD). Novartis' oral therapy CNP520 will be the lead molecule and further compounds from both company's pre-clinical BACE inhibitor programs may be considered as follow-on molecules.
AstraZeneca and Valeant Pharmaceuticals to partner on brodalumab
- Details
- Category: AstraZeneca
AstraZeneca has entered into a collaboration agreement with Valeant Pharmaceuticals International, Inc. under which it will grant an exclusive license for Valeant to develop and commercialise brodalumab. Brodalumab is an IL-17 receptor monoclonal antibody in development for patients with moderate-to-severe plaque psoriasis and psoriatic arthritis.
Novo Nordisk plans 2 billion US dollar investment in new production facilities in Clayton, North Carolina and Måløv, Denmark
- Details
- Category: Novo Nordisk
Novo Nordisk plans to invest an estimated 2 billion US dollars over the next five years in new production facilities in Clayton, North Carolina, US and Måløv, Denmark. The expansions will help Novo Nordisk meet the increasing worldwide demand for its diabetes medicines.
AstraZeneca and Peregrine Pharmaceuticals to collaborate on immuno-oncology combination clinical trial
- Details
- Category: AstraZeneca
AstraZeneca today announced that it has entered into a clinical trial collaboration with Peregrine Pharmaceuticals, Inc. to evaluate the safety and efficacy of Peregrine's investigational phosphatidylserine (PS)-signalling pathway inhibitor, bavituximab, in combination with AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736).
Novartis acquires all remaining rights to GSK's Ofatumumab to develop treatments for MS and other autoimmune indications
- Details
- Category: Novartis
Novartis announced today that it has entered into an agreement to acquire all remaining rights to Ofatumumab from GlaxoSmithKline plc (GSK). Ofatumumab, a fully human monoclonal antibody which targets CD20, is being developed for relapsing remitting multiple sclerosis (RRMS) and other autoimmune indications.
More Pharma News ...
- Sanofi, Evotec and Apeiron Biologics enter collaboration to develop novel small molecule immuno-oncology treatments
- Boehringer Ingelheim and Circuit Therapeutics announce new collaboration to discover novel medicines for obesity
- "Roche Continents" fosters innovation in science and art
- AstraZeneca and Heptares Therapeutics enter agreement to develop novel immuno-oncology treatments
- MedImmune and Mirati Therapeutics partner on immuno-oncology combination in lung cancer
- Pfizer and Synthon enter into U.S. commercialization agreement for potential generic treatment of multiple sclerosis
- Bristol-Myers Squibb establishes collaborative Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S.